{"id":496773,"date":"2020-07-17T14:08:01","date_gmt":"2020-07-17T14:08:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=496773"},"modified":"2020-07-17T14:08:01","modified_gmt":"2020-07-17T14:08:01","slug":"synovial-sarcoma-pipeline-insight-2020","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/synovial-sarcoma-pipeline-insight-2020_496773.html","title":{"rendered":"Synovial Sarcoma Pipeline Insight, 2020"},"content":{"rendered":"
\"Synovial<\/a><\/div>\n

(Albany, US), DelveInsight has launched a new report on Synovial Sarcoma Pipeline<\/a><\/span><\/strong><\/p>\n

Synovial Sarcoma Pipeline Insight<\/strong>, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Synovial Sarcoma market. A detailed picture of the Synovial Sarcoma pipeline landscape is provided, which includes the disease overview and Synovial Sarcoma treatment guidelines. The assessment part of the report embraces in-depth Synovial Sarcoma commercial assessment and clinical assessment of the Synovial Sarcoma pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Synovial Sarcoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

Synovial sarcoma (SS) is a rare malignancy of mesenchymal origin, accounting for approximately 8–10% of all soft tissue sarcomas (STS). Despite its name, synovial sarcoma is not related to the synovial tissues that are a part of the joints. The disease starts most commonly in the legs or arms, but can appear in any part of the body. Being a high-grade tumor, it spreads to distant sites in about half of the cases. Synovial sarcoma is generally divided into three histological subtypes: monophasic, biphasic, and poorly differentiated. The exact underlying cause of synovial sarcoma is poorly understood. However, studies indicate that translocation between chromosome X and chromosome 18 appears to play a role in the development of synovial sarcoma. This translocation is specific to synovial sarcoma and is often used to diagnose the condition. In the early stages of the condition, synovial sarcoma may cause no noticeable signs or symptoms but as the tumor grows larger, affected people may notice a lump or swelling. In some cases, the tumor can limit the range of motion or cause numbness and\/or pain if it presses on nearby nerves.<\/p>\n

 \"\"<\/p>\n

Request for Free sample page:-  https:\/\/www.delveinsight.com\/sample-request\/synovial-sarcoma-pipeline-insight<\/a><\/span><\/strong><\/p>\n

Synovial Sarcoma Pipeline development activities <\/strong><\/p>\n

The report provides insights into: <\/p>\n